Cargando…

Chitinase-3 like-protein-1, matrix metalloproteinase -9 and positive intracranial arterial remodelling

INTRODUCTION: Positive intracranial arterial remodelling is a dilated lesion of the large intracranial vessels; however, its pathogenesis is currently unknown. Some studies have identified chitinase-3 like-protein-1 (YKL-40) and matrix metalloproteinase (MMP)-9 as circulating inflammatory factors in...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Ming, Zhou, Dongyang, He, Junhui, Bai, Hongying, Li, Qianqian, Xu, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119585/
https://www.ncbi.nlm.nih.gov/pubmed/37091521
http://dx.doi.org/10.3389/fnagi.2023.1154116
_version_ 1785029047308255232
author Tang, Ming
Zhou, Dongyang
He, Junhui
Bai, Hongying
Li, Qianqian
Xu, Hui
author_facet Tang, Ming
Zhou, Dongyang
He, Junhui
Bai, Hongying
Li, Qianqian
Xu, Hui
author_sort Tang, Ming
collection PubMed
description INTRODUCTION: Positive intracranial arterial remodelling is a dilated lesion of the large intracranial vessels; however, its pathogenesis is currently unknown. Some studies have identified chitinase-3 like-protein-1 (YKL-40) and matrix metalloproteinase (MMP)-9 as circulating inflammatory factors involved in positive vascular remodelling. Herein, we aimed to investigate the relationship between changes in serum YKL-40 and MMP-9 levels and positive intracranial arterial remodelling in patients with cerebral small vessel disease (CSVD). METHODS: A total of 110 patients with CSVD were selected. Patients with brain arterial remodelling (BAR) scores >1 times the standard deviation were defined as the positive intracranial artery remodelling group (n = 21 cases), and those with BAR scores ≤1 times the standard deviation were defined as the non-positive intracranial artery remodelling group (n = 89 cases). Serum YKL-40 and MMP-9 levels were measured using an enzyme-linked immunosorbent assay kit. Factors influencing positive intracranial artery remodelling using binary logistic regression analysis and predictive value of YKL-40 and MMP-9 for positive intracranial arterial remodelling in patients with CSVD were assessed by a subject receiver operating characteristic curve. RESULTS: Statistically significant differences in serum YKL-40 and MMP-9 levels were observed between the positive and non-positive remodelling groups (p < 0.05). The integrated indicator (OR = 9.410, 95% CI: 3.156 ~ 28.054, P<0.01) of YKL-40 and MMP-9 levels were independent risk factors for positive intracranial arterial remodelling. The integrated indicator (OR = 3.763, 95% CI: 1.884 ~ 7.517, p < 0.01) of YKL-40 and MMP-9 were independent risk factors for positive arterial remodelling in posterior circulation, but were not significantly associated with positive arterial remodelling in anterior circulation (p > 0.05). The area under the curve for YKL-40 and MMP-9 diagnostic positive remodelling was 0.778 (95% CI: 0.692–0.865, p < 0.01) and 0.736 (95% CI: 0.636–0.837, p < 0.01), respectively. DISCUSSION: Elevated serum YKL-40 and MMP-9 levels are independent risk factors for positive intracranial arterial remodelling in patients with CSVD and may predict the presence of positive intracranial arterial remodelling, providing new ideas for the mechanism of its occurrence and development and the direction of treatment.
format Online
Article
Text
id pubmed-10119585
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101195852023-04-22 Chitinase-3 like-protein-1, matrix metalloproteinase -9 and positive intracranial arterial remodelling Tang, Ming Zhou, Dongyang He, Junhui Bai, Hongying Li, Qianqian Xu, Hui Front Aging Neurosci Aging Neuroscience INTRODUCTION: Positive intracranial arterial remodelling is a dilated lesion of the large intracranial vessels; however, its pathogenesis is currently unknown. Some studies have identified chitinase-3 like-protein-1 (YKL-40) and matrix metalloproteinase (MMP)-9 as circulating inflammatory factors involved in positive vascular remodelling. Herein, we aimed to investigate the relationship between changes in serum YKL-40 and MMP-9 levels and positive intracranial arterial remodelling in patients with cerebral small vessel disease (CSVD). METHODS: A total of 110 patients with CSVD were selected. Patients with brain arterial remodelling (BAR) scores >1 times the standard deviation were defined as the positive intracranial artery remodelling group (n = 21 cases), and those with BAR scores ≤1 times the standard deviation were defined as the non-positive intracranial artery remodelling group (n = 89 cases). Serum YKL-40 and MMP-9 levels were measured using an enzyme-linked immunosorbent assay kit. Factors influencing positive intracranial artery remodelling using binary logistic regression analysis and predictive value of YKL-40 and MMP-9 for positive intracranial arterial remodelling in patients with CSVD were assessed by a subject receiver operating characteristic curve. RESULTS: Statistically significant differences in serum YKL-40 and MMP-9 levels were observed between the positive and non-positive remodelling groups (p < 0.05). The integrated indicator (OR = 9.410, 95% CI: 3.156 ~ 28.054, P<0.01) of YKL-40 and MMP-9 levels were independent risk factors for positive intracranial arterial remodelling. The integrated indicator (OR = 3.763, 95% CI: 1.884 ~ 7.517, p < 0.01) of YKL-40 and MMP-9 were independent risk factors for positive arterial remodelling in posterior circulation, but were not significantly associated with positive arterial remodelling in anterior circulation (p > 0.05). The area under the curve for YKL-40 and MMP-9 diagnostic positive remodelling was 0.778 (95% CI: 0.692–0.865, p < 0.01) and 0.736 (95% CI: 0.636–0.837, p < 0.01), respectively. DISCUSSION: Elevated serum YKL-40 and MMP-9 levels are independent risk factors for positive intracranial arterial remodelling in patients with CSVD and may predict the presence of positive intracranial arterial remodelling, providing new ideas for the mechanism of its occurrence and development and the direction of treatment. Frontiers Media S.A. 2023-04-06 /pmc/articles/PMC10119585/ /pubmed/37091521 http://dx.doi.org/10.3389/fnagi.2023.1154116 Text en Copyright © 2023 Tang, Zhou, He, Bai, Li and Xu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Aging Neuroscience
Tang, Ming
Zhou, Dongyang
He, Junhui
Bai, Hongying
Li, Qianqian
Xu, Hui
Chitinase-3 like-protein-1, matrix metalloproteinase -9 and positive intracranial arterial remodelling
title Chitinase-3 like-protein-1, matrix metalloproteinase -9 and positive intracranial arterial remodelling
title_full Chitinase-3 like-protein-1, matrix metalloproteinase -9 and positive intracranial arterial remodelling
title_fullStr Chitinase-3 like-protein-1, matrix metalloproteinase -9 and positive intracranial arterial remodelling
title_full_unstemmed Chitinase-3 like-protein-1, matrix metalloproteinase -9 and positive intracranial arterial remodelling
title_short Chitinase-3 like-protein-1, matrix metalloproteinase -9 and positive intracranial arterial remodelling
title_sort chitinase-3 like-protein-1, matrix metalloproteinase -9 and positive intracranial arterial remodelling
topic Aging Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119585/
https://www.ncbi.nlm.nih.gov/pubmed/37091521
http://dx.doi.org/10.3389/fnagi.2023.1154116
work_keys_str_mv AT tangming chitinase3likeprotein1matrixmetalloproteinase9andpositiveintracranialarterialremodelling
AT zhoudongyang chitinase3likeprotein1matrixmetalloproteinase9andpositiveintracranialarterialremodelling
AT hejunhui chitinase3likeprotein1matrixmetalloproteinase9andpositiveintracranialarterialremodelling
AT baihongying chitinase3likeprotein1matrixmetalloproteinase9andpositiveintracranialarterialremodelling
AT liqianqian chitinase3likeprotein1matrixmetalloproteinase9andpositiveintracranialarterialremodelling
AT xuhui chitinase3likeprotein1matrixmetalloproteinase9andpositiveintracranialarterialremodelling